

INFORME DE BÚSQUEDA DE PATENTES PARA EL No de Radicación: 09-3460						
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boleanos utilizados)						
Palabras clave utilizadas		EphA2 antibodies				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA		C07K16/28				
BASES DE DATOS CONSULTADAS.						
Google patents		The lens		Patbase		
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS (documentos patentes, literatura no patente etc...)						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
EUROPEA						
USPTO						
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
US2004028685						
US 6180370						
BÚSQUEDA DE SECUENCIAS						
Número de depósito / patente y N° de secuencia % de identidad						
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest	

CRITERIOS DE BÚSQUEDA / UNIDAD DE INVENCION (Pantallazos)

PatBase Search Results: 9	-	Search query	results (5):	24 1	November near	2015 2
Search history						
Search 1:			TAC=(antibody) (Results 100000)			
Search 2:			Eph (Results 723)			
Search 3:			EphA2 (Results 276)			
Search 4:			ECK (Results 5170)			
Search 5:			1 near 2 (Results 9)			
Search 6:			1 near 3 (Results 50)			
Search 7:			1 near 4 (Results 0)			
1) Family number: 42182587 (US2001024650A)			PatBase			

Title: ARTERY - AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR

Abstract: Source: US2001024650A Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

2) Family number: 20734476 (US2004136983A)

© PatBase

Title: METHODS FOR INHIBITING ANGIOGENESIS BY EPHB RECEPTOR ANTAGONISTS

Abstract: Source: US2004136983A The present application describes methods of inhibiting or stimulating angiogenesis in a mammal comprising administering to the mammal an effective amount of an Eph receptor antagonist or agonist, respectively. Articles of manufacture for use in relation to these methods are also described.

3) Family number: 29787059 (US2004028685A)

© PatBase

Title: EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

Abstract: Source: US2004028685A The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K_{off}, thereby, inhibiting tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

4) Family number: 30877581 (US2006140957A)

© PatBase

Title: EPH/EPHRIN MEDIATED MODULATION OF CELL ADHESION AND TUMOUR CELL METASTASIS

Abstract:

Source: US2006140957A Methods and compositions for modulating ephrin/Eph receptor-mediated cell adhesion and/or cell repulsion are provided, particularly in relation to preventing, inhibiting or delaying tumour cell metastasis through modulation of Eph receptor-ephrin binding interactions and subsequent Eph receptor signalling. Particular agents useful according to the invention are agents which interfere with a ephrin-Eph receptor binding such as soluble ephrins and Eph receptors and antibodies directed to ephrins and Eph receptors, ephrin-cytotoxic drug conjugates which kill tumour cells, metalloprotease inhibitors and inhibitors of protein tyrosine phosphatase activity.

5) Family number: 32633148 (US2006039904A)

© PatBase

Title: EPH RECEPTOR FC VARIANTS WITH ENHANCED ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY ACTIVITY

Abstract: Source: US2006039904A The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants

comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., FcγR, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.

6) Family number: 32653284 (WO06022295A1)

© PatBase

Title: ANTI-EPHRIN B2 ANTIBODY

Abstract: It is intended to provide an antibody or an antibody fragment capable of binding to ephrin B2 and inhibiting the angiogenetic activity of ephrin B2 and the proliferation activity of a mammary gland tissue. Namely, an antibody or an antibody fragment binding to ephrin B2 which is expressed in cells of a tissue with angiogenesis such as a tumor; a method of immunologically detecting ephrin B2 or a cell expressing ephrin B2 and a detection reagent therefor with the use of the antibody or the antibody fragment as described above; a diagnostic or a remedy for a disease, in which ephrin B2 participates, by using the antibody or the antibody fragment as described above; and a hybridoma producing the above-described antibody.

7) Family number: 32879294 (US2006121042A)

© PatBase

Title: MODULATION OF ANTIBODY SPECIFICITY BY TAILORING THE AFFINITY TO COGNATE ANTIGENS

Abstract: Source: US2006121042A The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the Ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more Ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/Ephrin Modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.

8) Family number: 38528941 (US2009324618A)

© PatBase

Title: NOVEL SIGNATURE SELF RENEWAL GENE EXPRESSION PROGRAMS

Abstract: Source: US2009324618A The present invention relates to compounds and methods which are useful in molecular investigations of target genes, as well as their encoded RNAs and protein, belonging to signature self renewal programs in leukemia and/or cancer stem cells. Data herein shows that leukemia stem cells can be generated from committed progenitors without widespread reprogramming of gene expression, and wherein a leukemia self-renewal associated signature is activated in the process.

9) Family number: 43354345 (US2009306186A)

© PatBase

Title: NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE

Abstract: Source: US2009306186A There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex,

termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR).